New Insights on PPAR Agonists For Cardiovascular Disease

1
New Insights on PPAR Agonists For Cardiovascular
Disease
2
Global Estimates of Type 2 Diabetes in the Adult
Population
3
Reasons for Death UKPDS 33 Intensive Rx
4
Glucose Perturbations in Patients With CAD
5
UKPDS 35 Impact of Increasing A1c on
Cardiovascular Disease in T2DM
6
UKPDS 33 Blood Glucose and Vascular Risk in
Diabetes
7
ACCORD and ADVANCE Effects of Intensive Glucose
Control on CV Disease and Mortality
8
CARDS Benefit With Atorvastatin in T2DM
9
UKPDS 38 Blood Pressure Reduction and Vascular
Risk
10
STENO-2 Effect of Multifactorial Management on
Outcomes in Type 2 Diabetes
11
PPAR-a and PPAR-g Agonists Target Systems
12
Cardiovascular Outcomes Trials With PPAR-a Acting
Agents Fibrates
13
ACCORD Lipid Effect of Fenofibrate on Lipid
Parameters and CV Outcomes
14
Effects of Fibrates on Cardiovascular Events A
Systematic Review and Meta-Analysis
15
Effects of Fibrates on Coronary Events by
Cholesterol and TG Level
16
CV Events With PPAR-g Agonists
17
PROactive Time to Secondary CV Composite Endpoint
18
Pioglitazone and Risk of CVD in T2DM
Meta-Analysis
19
CHICAGO Effect of Pioglitazone on Carotid Artery
Intima-media Thickness
20
(No Transcript)
21
PPAR-g Agonists Lipoprotein Effects
22
Effect of Pioglitazone on Atheroma Volume vs
Other CV Agents
23
Genes Uniquely Regulated by the TZDs
24
Expected Targets for Dual PPAR-a/g Agonists
25
Dual PPAR-a/g Agonists
26
Dual a/g PPAR Agonist Effect of Muraglitazar on
Lipid Parameters
27
Effect of Muraglitazar on Cardiovascular Outcomes
28
GLAD Effect of Tesaglitazar vs Pioglitazone on
Lipid Measures
29
Effect of Tesaglitazar on Serum Creatinine and
Glomerular Filtration
30
The Concept of a Balanced Dual PPAR-a/g Agonist
31
PPAR-a/g Transactivation Profiles of
Rosiglitazone and Pioglitazone
32
Aleglitazars Dual PPAR-a/g Transactivation
Profile
33
Gene Profile of Dual PPAR-a/g Agonists
34
SYNCHRONY Effect of Aleglitazar on A1c in T2DM
35
SYNCHRONY Effect of Aleglitazar on Lipid
Measures in T2DM
36
SYNCHRONY Effect of Aleglitazar on LDL Particle
Size and Number in T2DM
37
SYNCHRONY Cardiovascular Safety
38
SYNCHRONY Effect of Aleglitazar on Serum
Creatinine in T2DM
39
SESTA R Impact of Supratherapeutic Doses of
Aleglitazar on Renal Function in T2DM
40
ALENEPHRO Objective and Study Design
41
ALENEPHRO Effect of Aleglitazar on eGFR and SCr
in Patients With Renal Impairment
42
ALECARDIO Aleglitazar in Patients With T2DM and
ACS
43
Program Summary
44
(No Transcript)
45
(No Transcript)
46
(No Transcript)
47
(No Transcript)